On July 13, 2025, Cowen & Co. updated their rating for Moderna (NASDAQ:MRNA) to "Hold," with the stock priced at $33.64. This update, reported by Benzinga, highlighted Moderna as one of the top large-cap gainers from the previous week. Moderna is a biotechnology company known for its mRNA technology, particularly its COVID-19 vaccine, Spikevax.
Moderna's stock saw a 4.5% increase following the FDA's full approval of Spikevax for high-risk children aged six months to 11 years. Previously, the vaccine was only available to this age group under Emergency Use Authorization. This approval allows Spikevax to be used for all adults aged 65 and above, and individuals aged six months through 64 years who are at increased risk.
The FDA's approval marks a significant milestone for Moderna, expanding its reach in the pediatric population. Stéphane Bancel, CEO of Moderna, emphasized the importance of vaccination in protecting young children, especially those with underlying medical conditions. The updated vaccine will be available for eligible patients during the 2025-2026 U.S. vaccination season.
Despite the positive news, Moderna's stock price reflects a decrease of 1.87%, or $0.64, trading between $33.21 and $34.15. Over the past year, the stock has seen a high of $127.20 and a low of $23.15. Moderna's market capitalization is approximately $13 billion, with a trading volume of 6,922,580 shares.
In related news, a High Court ruling in July 2024 declared one of Moderna's mRNA technology patents invalid while upholding another. This impacts the legal landscape with competitors like Pfizer and BioNTech's Comirnaty vaccine. Despite these challenges, Moderna continues to focus on expanding its vaccine offerings and maintaining its position in the biotechnology industry.
